Cargando…

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review

BACKGROUND: Understanding molecular pathogenesis of head and neck squamous cell carcinomas (HNSCC) has considerably improved in the last decades. As a result, novel therapeutic strategies have evolved, amongst which are epidermal growth factor receptor (EGFR)-targeted therapies. With the exception o...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kort, W. W. B., Spelier, S., Devriese, L. A., van Es, R. J. J., Willems, S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956931/
https://www.ncbi.nlm.nih.gov/pubmed/33686517
http://dx.doi.org/10.1007/s40291-021-00518-6
_version_ 1783664545366016000
author de Kort, W. W. B.
Spelier, S.
Devriese, L. A.
van Es, R. J. J.
Willems, S. M.
author_facet de Kort, W. W. B.
Spelier, S.
Devriese, L. A.
van Es, R. J. J.
Willems, S. M.
author_sort de Kort, W. W. B.
collection PubMed
description BACKGROUND: Understanding molecular pathogenesis of head and neck squamous cell carcinomas (HNSCC) has considerably improved in the last decades. As a result, novel therapeutic strategies have evolved, amongst which are epidermal growth factor receptor (EGFR)-targeted therapies. With the exception of cetuximab, targeted therapies for HNSCC have not yet been introduced into clinical practice. One important aspect of new treatment regimes in clinical practice is presence of robust biomarkers predictive for therapy response. METHODS: We performed a systematic search in PubMed, Embase and the Cochrane library. Articles were included if they investigated a biomarker for targeted therapy in the EGFR-PI3K-AKT-mTOR-pathway. RESULTS: Of 83 included articles, 52 were preclinical and 33 were clinical studies (two studies contained both a preclinical and a clinical part). We classified EGFR pathway inhibitor types and investigated the type of biomarker (biomarker on epigenetic, DNA, mRNA or protein level). CONCLUSION: Several EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers have been researched for HNSCC but few of the investigated biomarkers have been adequately confirmed in clinical trials. A more systematic approach is needed to discover proper biomarkers as stratifying patients is essential to prevent unnecessary costs and side effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40291-021-00518-6.
format Online
Article
Text
id pubmed-7956931
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79569312021-03-28 Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review de Kort, W. W. B. Spelier, S. Devriese, L. A. van Es, R. J. J. Willems, S. M. Mol Diagn Ther Systematic Review BACKGROUND: Understanding molecular pathogenesis of head and neck squamous cell carcinomas (HNSCC) has considerably improved in the last decades. As a result, novel therapeutic strategies have evolved, amongst which are epidermal growth factor receptor (EGFR)-targeted therapies. With the exception of cetuximab, targeted therapies for HNSCC have not yet been introduced into clinical practice. One important aspect of new treatment regimes in clinical practice is presence of robust biomarkers predictive for therapy response. METHODS: We performed a systematic search in PubMed, Embase and the Cochrane library. Articles were included if they investigated a biomarker for targeted therapy in the EGFR-PI3K-AKT-mTOR-pathway. RESULTS: Of 83 included articles, 52 were preclinical and 33 were clinical studies (two studies contained both a preclinical and a clinical part). We classified EGFR pathway inhibitor types and investigated the type of biomarker (biomarker on epigenetic, DNA, mRNA or protein level). CONCLUSION: Several EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers have been researched for HNSCC but few of the investigated biomarkers have been adequately confirmed in clinical trials. A more systematic approach is needed to discover proper biomarkers as stratifying patients is essential to prevent unnecessary costs and side effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40291-021-00518-6. Springer International Publishing 2021-03-08 2021 /pmc/articles/PMC7956931/ /pubmed/33686517 http://dx.doi.org/10.1007/s40291-021-00518-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Systematic Review
de Kort, W. W. B.
Spelier, S.
Devriese, L. A.
van Es, R. J. J.
Willems, S. M.
Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
title Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
title_full Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
title_fullStr Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
title_full_unstemmed Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
title_short Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
title_sort predictive value of egfr-pi3k-akt-mtor-pathway inhibitor biomarkers for head and neck squamous cell carcinoma: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956931/
https://www.ncbi.nlm.nih.gov/pubmed/33686517
http://dx.doi.org/10.1007/s40291-021-00518-6
work_keys_str_mv AT dekortwwb predictivevalueofegfrpi3kaktmtorpathwayinhibitorbiomarkersforheadandnecksquamouscellcarcinomaasystematicreview
AT speliers predictivevalueofegfrpi3kaktmtorpathwayinhibitorbiomarkersforheadandnecksquamouscellcarcinomaasystematicreview
AT devriesela predictivevalueofegfrpi3kaktmtorpathwayinhibitorbiomarkersforheadandnecksquamouscellcarcinomaasystematicreview
AT vanesrjj predictivevalueofegfrpi3kaktmtorpathwayinhibitorbiomarkersforheadandnecksquamouscellcarcinomaasystematicreview
AT willemssm predictivevalueofegfrpi3kaktmtorpathwayinhibitorbiomarkersforheadandnecksquamouscellcarcinomaasystematicreview